Developing a cancer drug without Big Pharma: this hospital shows it can be done

Original Article ↗ Hacker News Discussion ↗

Developing new cancer treatments outside of Big Pharma raises hard questions about cost, regulation, and incentives. Commenters contrast promising but hard-to-patent ideas like high‑dose intravenous vitamin C with the reality that rigorous phase III trials and regulatory dossiers can cost tens or hundreds of millions of euros. Examples such as a Dutch hospital running a large immunotherapy trial with charity funding, Cuba’s lung cancer “vaccine,” and underground trials for the wealthy highlight both the possibility of non‑corporate drug development and the practical barriers that keep most therapies within the current pharma‑driven system.

Unpatentable / “Simple” Cancer Therapies (Vitamin C focus)

  • Major subthread on high‑dose IV vitamin C as an adjunct cancer therapy.
  • Pro‑side:
    • Cites mechanistic work and clinical data suggesting cytotoxic effects on cancer cells, especially with IV high doses versus ineffective oral dosing.
    • Points to umbrella reviews, RCTs in advanced pancreatic and colorectal cancer, and many case reports indicating longer survival, slower progression, and better quality of life when combined with standard chemo.
    • Argues research is underfunded because vitamin C is not patentable, not because of lack of promise.
  • Skeptical side:
    • Labels high‑dose vitamin C as recurrent “quackery.”
    • Notes vitamin C is broadly cytotoxic at high doses, cancers often evolve resistance, and evidence so far shows at best survival extension, not cures.
    • Cites data that some antioxidants worsen cancer; counters that this is about other vitamins, not C.
  • Both sides agree: more and better trials would be needed to settle efficacy; safety of vitamin C itself is mostly established.

Cost, Complexity, and Regulation of Trials

  • Many comments emphasize that rigorous clinical trials are inherently expensive and logistically hard:
    • Need for ethical design, monitoring, manufacturing quality, liability coverage, and regulatory‑grade documentation.
    • Phase III cancer trials can run into tens or hundreds of millions, with high per‑patient costs and large, complex dossiers.
  • Disagreement over how much of this is genuine scientific/ethical necessity versus bureaucracy, CRO markups, and regulatory accretion.

Hospital‑Led Cancer Drug Development

  • The discussed hospital‑run phase III trial (TIL therapy) is seen as a notable proof that large, late‑stage oncology trials can be done largely outside Big Pharma, with charity and institutional support.
  • Others note it still relies on existing regulatory structures and isn’t a fully “pharma‑free” model.

Pharma Incentives, Doctors, and Systemic Critiques

  • One camp argues: effective treatments can’t be ignored for decades because doctors, patients, and researchers are strongly motivated by outcomes and recognition.
  • Counter‑camp:
    • Doctors face debt, institutional pressure, and regulatory risk; they rarely drive unproven, non‑commercial ideas.
    • Big‑trial selection is shaped by patents, profit, egos, and academic incentives, not just science.
    • Many potentially useful but unpatentable or off‑label options never get definitive trials.

Cancer Vaccines and Immunotherapy

  • Cuba’s CIMAvax and other “cancer vaccines” are discussed as therapeutic vaccines: they induce an immune response against tumor‑related targets (e.g., EGF/EGFR), rather than preventing initial cancer.

Drug Discovery Limits and Reform Ideas

  • Several participants highlight:
    • Poor predictive power of animal and preclinical models (especially in neurodegeneration and oncology).
    • ~10% success rate from phase I to approval; much of the total cost comes from failed candidates.
    • Calls for better mechanistic modeling, AI‑assisted prediction, and alternative funding models, but recognition that regulation and patient safety limit “move fast and break things.”

Ethics, Exploitation, and Underground Trials

  • Proposals to run cheap trials on underserved populations or via apps draw strong criticism as coercive and scientifically weak.
  • Claims that billionaires run private “underground” trials; not substantiated or deeply explored in the thread, but mentioned as a symptom of mistrust in formal systems.

AI and Future Disruption

  • Some expect AI to transform drug discovery, forecasting efficacy from preclinical data and reducing failed trials.
  • Others caution that biology’s complexity, ethics, and centralized regulation make “Uber‑style” disruption unlikely.

Anecdotes and Fringe Treatments

  • The thread contains personal anecdotes (e.g., alternative protocols for Parkinson’s) and direct promotion of specific clinics/protocols.
  • These are presented without corroborating data and implicitly treated by others as outside evidence, not as established therapies.